Stopping Cancer Before It Starts

Antiva is developing novel topical therapies to treat pre-cancerous cervical lesions as well as the HPV infections that cause these lesions. Currently, there is no treatment for HPV infection; women must wait and see whether their infection clears by itself or progresses to more advanced disease. We are developing a first-in-class therapy that would give women the ability to treat themselves in the privacy of their own homes when their infection is first diagnosed. Our therapy also provides a non-surgical option for women whose disease is more advanced.

Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide by developing a simple and convenient non-surgical approach to treat HPV and precancerous lesions, supporting the World Health Organization’s global Cervical Cancer Elimination Initiative.

Antiva in the

January 6, 2022

Antiva Biosciences Named Winner of Global Women’s HealthTech Award by World Bank Group and Consumer Technology Association Read more

November 2, 2021

Antiva Biosciences Closes $31 Million Series D Equity Financing Read more

April 21, 2021

Antiva Biosciences Appoints Clifford Samuel to Board of Directors Read more